Serum samples from patients with connective tissue diseases often contain antibodies against cellular components.' In some cases the presence of these autoantibodies is specifically associated with a certain syndrome or disease, and therefore useful as diagnostic marker. Good examples of such markers are anti-Sm antibodies in systemic lupus erythematosus and anti-Jo-l in patients with polymyositis.' Serological support for the diagnosis of rheumatoid arthritis is not well established and mainly based on the presence of rheumatoid factors. Rheumatoid factor is not present in all patients with rheumatoid arthritis, however, and can also be found in serum samples from patients with other (autoimmune) diseases and even in healthy subjects.2 Therefore the availability of another specific serological marker for rheumatoid arthritis would be useful.
Three other antibody specificities have been described as being specific for rheumatoid arthritis, all three directed against different components of epitheial cells-namely, antibodies against intermediate filaments in cultured cells, antibodies against a keratin-like component in rat oesophageal epithelium, and the antiperinuclear factor, consisting of antibodies directed against a component in human buccal mucosa cells.
All three specificities are detectable by indirect immunofluorescence. Antibodies against intermediate filaments in rheumatoid serum samples have specificity for the intermediate filament proteins vimentin or cytokeratin, or both, in cultured cells and are mostly of the IgM class.5 Antibodies against vimentin have been found in 54 800/o of patients with rheumatoid arthritis,3 4 &-8 and antibodies against cytokeratin in 31-40% of such patients.3 4 8 Antibodies against intermediate filaments, however, are not particularly specific for rheumatoid arthritis and are often present in other diseases also,3 4 9 10 and have even been found in 14-63% of healthy subjects. 3 4 " Antibodies against keratin, detectable by immunofluorescence on rat oesophagus tissue, and first described in 1979 by Young and coworkers,'2 are found in 36-690/o ofrheumatoid serum samples and in only 0-4-2% of healthy control serum samples.4 8 12-18 These antibodies are predominantly of the IgG class and can also be found in synovial fluid of patients with rheumatoid arthritis. 14 The antiperinuclear factor was originally described by Nienhuis and collaborators,'9 who demonstrated its high specificity for rheumatoid arthritis. The antibodies, mostly of the IgG type, are directed against a protein in the 0-5-4 tim spherical shaped keratohyalin granules ins the cytoplasm of buccal mucosa cells and are found in 48-86% of serum samples 1132 and synovial fluids from patients with rheumatoid arthritis.'9 Westgeest et al found that antiperinuclear factor titres correlate with the severity of disease,21 and this is most clearly seen in patients without the rheumatoid factor. An increased prevalence of antiperinuclear factor has been described in certain other syndromes.2212 31 The major drawback of the antiperinuclear factor immunofluorescence test is the nature of the substrate. Most authors report that only a small percentage of buccal mucosa cell donors have antigen present in a satisfactory amount.'6 22 26-28 In this study we modified and improved the sensitivity of the antiperinuclear factor test and reassessed its specificity. Additionally, new data on the localisation and characterisation of the perinuclear factor are presented, and the pos- Systemic lupus erythematosus 33 21 Mixed connective tissue disease 21 5 Undifferentiated connective 20 10 tissue disease Sj6gren's syndrome 34 29 Systemic sclerosis 42 26 Lyme's disease 26 4 Healthy controls 51 6 $Diagnoses were reached according to published criteria.33
In contrast with other studies we found that at least 70% (35/50) Table 6 shows the results of experiments with various specific antibodies that were tested on (52) 10 (22) 3 (7) +l-5 (11) 1(2) 1(2) 3 (7) 4(9) 0(0) 1(2) 3 (7) Correlation between antiperinuclear factor and antikeratin antibodies (+ v +/-and -results) was calculated with the x2' test with Yates's correction. X2=6 11, 0 025 >p>0-01. 3A and B) show that in every cell an exact colocalisation of the perinuclear factor and profilaggrin could be seen. This exact colocalisation of profilaggrin with the perinuclear factor suggests that these two proteins may be identical. This possibility was tested in several ways. Firstly, competition of the binding of AKH1 (antifilaggrin) by increasing concentrations of antiperinuclear factor antibody did not abolish the binding of AKH1 to the keratohyalin granules. Therefore another epitope of profliaggrin or another antigen is recognised.
Secondly, when extracts of buccal mucosa cells on a western blot were probed with AKH1 (fig 4, lane 1) 
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Rat fiaggrmi Sjogren's syndrome than in those of healthy controls.22 23 30 31 Apparently the presence of antiperinuclear factor is not restricted to rheumatoid arthritis only.
Using an immunoelectron microscopical technique we confirmed that the perinuclear factor is localised in the keratohyalin granules of buccal mucosa cells (fig 2) . The whole body of the poorly structured granule seemed to contain the antigen, supporting the idea that these granules are an amorphous mixture of densely packed proteins. Only treatment with proteolytic enzymes seems able to untangle and degrade this mass, whereas denaturing by fixatives renders it even more inaccessible for antibodies ( (table  6 ). The same antikeratin antibodies were also tested on rat oesophagus sections, which resulted in a positive staining of the epithelial layer for cytokeratins 4 and 13 (monoclonal antibodies 6B10, 2D7, and K8.12), which are known to be present in oesophagus squamous epithelium. Although identical immunofluorescence staining was obtained with the rheumatoid serum samples containing antikeratin antibodies, subsequent two dimensional immunoblotting of a rat oesophagus extract with these samples did not show specific positive reactions with cytokeratin 4 or 13, whereas the monoclonal antibodies (6B10, 2D7, and K8.12) did react. It therefore is questionable whether antikeratin antibodies recognise a cytokeratin as the antigen. It is more likely that the antikeratin antibodyantigen is a protein associated with the cytokeratins in this type of epithelial cell. The name 'antikeratin antibodies', therefore, seems a most unfortunate choice and it would be better to refer to them as antirat oesophagus antibodies.
The association of the perinuclear factor with (pro)filaggrin, a protein which up to now has only been found in differentiated keratinocytes,54 suggests a differentiation-specific expression of the perinuclear factor. Our future research, therefore, will be directed towards establishing an in vitro culturing system for buccal mucosa keratinocytes to study the differentiation of these cells and the in vitro induction of the perinuclear factor.55
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